- Presentation and Question and Answer Session to be Webcast
beginning at 4:00 p.m. PT on January 9, 2018
WATERTOWN, Mass.--(BUSINESS WIRE)--Dec. 28, 2017--
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
make a formal presentation at the 36th Annual J.P. Morgan
Healthcare Conference on Tuesday, January 9, 2018. The presentation will
contain a business overview and an update on Enanta’s research and
development programs. A question and answer session with investors will
follow the presentation.
A live webcast of the presentation, as well as the question and answer
session that follows the presentation, will be accessible by visiting
the “Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com.
A replay of the webcasts will be available following the presentation
and will be archived for approximately 60 days.
Enanta Pharmaceuticals has used its robust,
chemistry-driven approach and drug discovery capabilities to become a
leader in the discovery of small molecule drugs for the treatment of
viral infections and liver diseases. Two protease inhibitors,
paritaprevir and glecaprevir, discovered and developed through Enanta’s
collaboration with AbbVie, have now been approved in jurisdictions
around the world as part of AbbVie’s direct-acting antiviral (DAA)
regimens for the treatment of hepatitis C virus (HCV) infection,
including the marketed regimens MAVYRET™(U.S.) /MAVIRET™ (ex-U.S.)
(glecaprevir/pibrentasvir) and VIEKIRA PAK® (U.S.)
(paritaprevir/ritonavir/ombitasvir/dasabuvir). Royalties and milestone
payments from the AbbVie collaboration are helping to fund Enanta’s
research and development efforts, which are currently focused on the
following disease targets: non-alcoholic steatohepatitis (NASH)/ primary
biliary cholangitis (PBC), respiratory syncytial virus (RSV) and
hepatitis B virus (HBV). Please visit www.enanta.com
for more information.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171228005016/en/
Source: Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc.